ViewRay's MRIdian to be Featured at Leading European Radiation Oncology Meeting

ViewRay's MRIdian to be Featured at Leading European Radiation Oncology Meeting

26 Clinical Presentations and Posters Highlight Benefits of MRI-Guided Radiation Therapy Across Applications and Growing Use of Adaptive Therapy

PR Newswire

CLEVELAND, April 23, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO), with a number of presentations and posters highlighting MRIdian research and clinical experience. The ESTRO meeting will be held April 26-30 in Milan, Italy.

(PRNewsfoto/ViewRay, Inc.)

MRIdian MRI-guided radiation therapy offers continuous, high-quality soft tissue visualization and automated beam-gating to improve the accuracy and precision of cancer treatment. The significant interest around MRIdian is reflected in more than 25 MRIdian presentations and posters accepted as part of ESTRO's Scientific Sessions. These abstracts were submitted by MRIdian users from around the world.

MRIdian Scientific Session presentations and posters will focus on clinical experience, patient outcomes, and response assessment and prediction, along with physics topics such as intra-fraction motion, commissioning and quality assurance. These presentations and posters will cover a wide array of clinical applications such as lung, pancreatic, cervical, breast, spinal, pelvic, abdominal, adrenal, and rectal cancers. The accepted MRIdian abstracts include clinical data from more than 150 patients and a significant number highlight MRIdian's adaptive therapy capabilities.

First pioneered by ViewRay in 2012, MRI-guided real-time on-table adaptive radiotherapy (MRI-Guided ROAR) represents a new paradigm in cancer treatment. It provides clinicians with the ability to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses.

ViewRay will host a Symposium on MRI-Guided ROAR on Sunday, April 28 from 1:15- 2:15 p.m. in Amber 8 Meeting Room. The symposium will highlight clinical experience with on-table adaptive therapy at both new and veteran MRIdian centers, with presentations by Enis Özyar, M.D., from Acibadem Maslak Hospital on the rapid introduction of on-table adaptive at their new MRIdian site, and by Miguel Palacios, medical physicist at Amsterdam University Medical Centers on their three years of MRIdian on-table adaptive therapy experience.

Visitors to ViewRay's booth #350 can hear first-hand MRIdian experience from clinicians at Gemelli ART/Università Cattolica del Sacro Cuore, Washington University School of Medicine, Acibadem Maslak Hospital, Institut Paoli-Calmettes Marseille and Heidelberg University Hospital. Featured topics include extracting info from MR images, prospective clinical trials, adaptive radiotherapy workflows, patient-specific QA, dosimetric properties and Monte Carlo model for the RayZR doublestack MLC, and the overall investment rationale.

Please visit for a detailed schedule of MRIdian presentations, posters and in-booth speakers.

About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

Intended Use: The MRIdian Linac System, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated.

Forward-Looking Statements: This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. These statements are subject to risks and uncertainties that could cause future results to differ materially from those referenced. Forward looking statements include, but are not limited to references to future MRIdian experience, clinical value and outcomes. Given these uncertainties, the reader is advised not to place any undue reliance on any forward-looking statements. Additional risk factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, government and regulatory uncertainty, including but not limited to obtaining authorizations to market and new tariffs and trade restrictions, and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at

Cision View original content to download multimedia:

SOURCE ViewRay, Inc.

Copyright CNW Group 2019